Key result
CHIP links to heightened cardiovascular disease risk primarily through enhanced inflammatory pathways.
Why the study?
Reanalysis of population-scale genomic datasets identified somatically acquired DNA mutations as an unexpected risk factor for cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Somatic mutations, including clonal hematopoiesis of indeterminate potential, represent a novel and important risk factor for various cardiovascular diseases.
Advances in population-scale genomic sequencing have greatly expanded the understanding of the inherited basis of cardiovascular disease (CVD). Reanalysis of these genomic datasets identified an unexpected risk factor for CVD, somatically acquired DNA mutations. In this review, we provide an overview of somatic mutations and their contributions to CVD. We focus on the most common and well-described manifestation, clonal hematopoiesis of indeterminate potential. We also review the currently available data regarding how somatic mutations lead to tissue mosaicism in various forms of CVD, including atrial fibrillation and aortic aneurism associated with Marfan Syndrome. Finally, we highlight future research directions given current knowledge gaps and consider how technological advances will enhance the discovery of somatic mutations in CVD and management of patients with somatic mutations.
No takes yet. Share an insight, caveat, or question.
Heimlich et al. (2022) conducted a review in Cardiovascular disease. Somatic mutations and clonal hematopoiesis of indeterminate potential (CHIP) was evaluated. Somatic mutations, notably clonal hematopoiesis of indeterminate potential (CHIP), act as major acquired risk factors for cardiovascular diseases primarily through enhanced inflammatory pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: